[go: up one dir, main page]

MX2018014779A - Virus vaccinia novedosos modificados geneticamente. - Google Patents

Virus vaccinia novedosos modificados geneticamente.

Info

Publication number
MX2018014779A
MX2018014779A MX2018014779A MX2018014779A MX2018014779A MX 2018014779 A MX2018014779 A MX 2018014779A MX 2018014779 A MX2018014779 A MX 2018014779A MX 2018014779 A MX2018014779 A MX 2018014779A MX 2018014779 A MX2018014779 A MX 2018014779A
Authority
MX
Mexico
Prior art keywords
vaccinia virus
modified vaccinia
polynucleotide encoding
new genetically
vaccinia
Prior art date
Application number
MX2018014779A
Other languages
English (en)
Other versions
MX382907B (es
Inventor
Nakao Shinsuke
Kawase Tatsuya
Nakamura Takafumi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018014779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2018014779A publication Critical patent/MX2018014779A/es
Publication of MX382907B publication Critical patent/MX382907B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un virus vaccinia genéticamente recombinante eficaz para la prevención o el tratamiento del cáncer. Específicamente, la presente invención proporciona un virus vaccinia que comprende dos polinucleótidos, un polinucleótido que codifica lL-7 y un polinucleótido que codifica lL-12; un kit de combinación de dos virus vaccinia, un virus vaccinia que comprende un polinucleótido que codifica IL-7 y un virus vaccinia que comprende un polinucleótido que codifica lL-12; y el uso de los dos virus vaccinia en combinación.
MX2018014779A 2016-05-30 2017-05-29 Virus vaccinia novedosos modificados genéticamente. MX382907B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016107481 2016-05-30
PCT/JP2017/019921 WO2017209053A1 (ja) 2016-05-30 2017-05-29 新規な遺伝子組換えワクシニアウイルス

Publications (2)

Publication Number Publication Date
MX2018014779A true MX2018014779A (es) 2019-08-29
MX382907B MX382907B (es) 2025-03-13

Family

ID=60477559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014779A MX382907B (es) 2016-05-30 2017-05-29 Virus vaccinia novedosos modificados genéticamente.

Country Status (28)

Country Link
EP (1) EP3480307B1 (es)
JP (1) JP6794442B2 (es)
KR (1) KR102357051B1 (es)
CN (1) CN109477089B (es)
AR (1) AR108630A1 (es)
AU (1) AU2017272721B2 (es)
BR (1) BR112018074881A2 (es)
CA (1) CA3026025A1 (es)
CO (1) CO2018013738A2 (es)
CY (1) CY1124314T1 (es)
DK (1) DK3480307T3 (es)
ES (1) ES2882538T3 (es)
HR (1) HRP20211145T1 (es)
HU (1) HUE054967T2 (es)
IL (1) IL263373B2 (es)
LT (1) LT3480307T (es)
MX (1) MX382907B (es)
MY (1) MY191091A (es)
PH (1) PH12018502548B1 (es)
PL (1) PL3480307T3 (es)
PT (1) PT3480307T (es)
RS (1) RS62077B1 (es)
RU (1) RU2757933C2 (es)
SG (1) SG11201810612TA (es)
SI (1) SI3480307T1 (es)
TW (1) TWI763673B (es)
UA (1) UA126380C2 (es)
WO (1) WO2017209053A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108686202A (zh) * 2017-04-06 2018-10-23 张晋宇 肿瘤免疫疗法
JP7274138B2 (ja) * 2017-11-30 2023-05-16 アステラス製薬株式会社 Ｓｃｒ欠失ワクシニアウイルス
US11802292B2 (en) * 2018-01-05 2023-10-31 Ottawa Hospital Research Institute Modified orthopoxvirus vectors
KR20210065976A (ko) 2018-09-26 2021-06-04 아스텔라스세이야쿠 가부시키가이샤 종양 용해성 백시니아 바이러스와 면역 체크포인트 저해제의 병용에 의한 암 요법 그리고 이것에 사용하기 위한 의약 조성물 및 조합 의약
CN110205307A (zh) * 2019-01-07 2019-09-06 西安彤盛生物科技有限公司 去除vgf基因的重组天坛株溶瘤痘苗病毒及制备和应用
US12409198B2 (en) 2019-05-14 2025-09-09 National University Corporation Tottori University Vaccinia virus that induces cell fusion and use thereof
EP3996743A4 (en) * 2019-07-12 2023-11-22 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. MANIPULATED VACCINE VIRUS
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114585376A (zh) * 2019-08-29 2022-06-03 安斯泰来制药有限公司 基因工程改造的溶瘤痘苗病毒及其使用方法
CN115103681B (zh) * 2020-02-18 2023-10-31 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4413040A1 (en) 2021-10-06 2024-08-14 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
CN119053340A (zh) 2021-10-06 2024-11-29 健玛保 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
EP4626446A1 (en) 2022-12-01 2025-10-08 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
WO2024181525A1 (ja) * 2023-03-01 2024-09-06 バイオコモ株式会社 抗がん剤、がん治療用医薬組成物、キット、及び活性化剤
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025242827A1 (en) 2024-05-22 2025-11-27 Genmab A/S Bispecific antibody against pd-l1 and cd137 in combination therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
JP2003512335A (ja) * 1999-10-18 2003-04-02 セント ビンセンツ ホスピタル アンド メディカル センター オブ ニューヨーク メラノーマワクチン並びにその製造方法及び使用方法
EP1644492B1 (en) 2003-06-18 2009-01-07 Genelux Corporation Modified recombinant vaccinia viruses, uses thereof
US20070036758A1 (en) 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP3293266B1 (en) * 2007-05-04 2025-12-24 University Health Network Il-12 immunotherapy for cancer
CA2794196A1 (en) * 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
US20130071430A1 (en) * 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2012151272A2 (en) * 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2758246C (en) * 2011-11-16 2013-02-12 Westport Power Inc. Method and apparatus for pumping fuel to a fuel injection system
EP3072966B1 (en) * 2013-11-21 2020-01-08 National University Corporation Tottori University Mitogen-activated protein kinase-dependent recombinant vaccinia virus (md-rvv) and use thereof
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus

Also Published As

Publication number Publication date
SI3480307T1 (sl) 2021-09-30
CY1124314T1 (el) 2022-07-22
IL263373B1 (en) 2023-06-01
KR20190014534A (ko) 2019-02-12
IL263373A (en) 2018-12-31
JP6794442B2 (ja) 2020-12-02
MY191091A (en) 2022-05-30
EP3480307A4 (en) 2020-01-01
WO2017209053A1 (ja) 2017-12-07
TW201809270A (zh) 2018-03-16
TWI763673B (zh) 2022-05-11
CA3026025A1 (en) 2017-12-07
BR112018074881A2 (pt) 2019-03-26
CO2018013738A2 (es) 2018-12-28
EP3480307B1 (en) 2021-06-23
HUE054967T2 (hu) 2021-10-28
EP3480307A1 (en) 2019-05-08
IL263373B2 (en) 2023-10-01
PL3480307T3 (pl) 2021-11-08
JPWO2017209053A1 (ja) 2019-03-28
PH12018502548B1 (en) 2023-08-30
AU2017272721A1 (en) 2018-12-13
PH12018502548A1 (en) 2019-04-08
KR102357051B1 (ko) 2022-02-03
MX382907B (es) 2025-03-13
CN109477089B (zh) 2022-05-24
LT3480307T (lt) 2021-09-27
RU2757933C2 (ru) 2021-10-25
RU2018146490A3 (es) 2020-11-17
PT3480307T (pt) 2021-07-26
CN109477089A (zh) 2019-03-15
DK3480307T3 (da) 2021-07-12
ES2882538T3 (es) 2021-12-02
HRP20211145T1 (hr) 2021-12-24
UA126380C2 (uk) 2022-09-28
RS62077B1 (sr) 2021-07-30
SG11201810612TA (en) 2018-12-28
AU2017272721B2 (en) 2023-03-30
RU2018146490A (ru) 2020-07-10
AR108630A1 (es) 2018-09-12

Similar Documents

Publication Publication Date Title
MX2018014779A (es) Virus vaccinia novedosos modificados geneticamente.
DK3687576T3 (da) Anvendelse af cannabidiol i kombination med norfenfluramin eller fenfluramin i behandling af epilepsi
EP3861472A4 (en) OPERATION OF MULTIPLE DEVICES TO IMPROVE THE SECURITY OF BIOMETRIC AUTHENTICATION
MX2019001669A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
BR112017018160A2 (pt) uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos
ECSP10010288A (es) Vectores de virus oncolíticos de viruela
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
AR109752A1 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
CO2018006642A2 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
MX2024003178A (es) Anticuerpos contra el lif y usos de los mismos.
MX2018004542A (es) Neoepítopos virales y sus usos.
MX2021002668A (es) Plataforma de virus oncolitico para tratar el cancer hematologico.
CL2017001579A1 (es) Copolímeros de polidialilamina reticulados para el tratamiento de la diabetes de tipo 2
AR103119A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal, incluyendo diarrea inducida por quimioterapia
EA202092824A1 (ru) Комбинированная терапия